• Experts in DNA sequencing and microfluidics.
• Our PHD founder created the technology.
• Recently INNOVATE UK recognised our technology as revolutionary.
• To date £2.5 million has been raised from private investors.
• Fully working diagnostic device – ready for commercialisation.

Targeting chest pains and heart attack

For millions of people cardiovascular disease can be difficult to detect because its symptoms may not be obvious, and because early stages of the disease may not cause any symptoms at all.

Current tests for the detection of there pathogen / antigen and biomarkers are not sensitive and or accurate enough to detect the early stages of these disease.

Late diagnosis makes treatment more complicated, increasingly costly and in some cases the treatment is less likely to succeed.

“Symptom based escalation of medical treatment is critical but often acts too late.“

Testing for markers instead, before symptoms arise, can catch disease much earlier.

Our QbQ technology aims at a wide-spread, cheap and accurate testing system for 100ds of conditions.

Testing at the clinic or at home.

What if instead there was a fast, highly sensitive, low-cost testing system available to doctors and clinicians that was available at the point of care.
GP Surgery’s, hospitals and health care centers and in the home.

For the detection of Cancer, Viruses, Heart Disease and Alzheimer’s.

Without the delay.

Genetic Microdevices have developed the QbQ device.

A simple solution (simple to use, complex technology on the inside).

Which carries out biological analysis of blood, saliva and other samples

• With ultra-high sensitivity

• Fast (<10 mins)

• Accurately

• At a low cost

Backed by science the QbQ – Now offers by far the earliest detection of Viruses, Dementia, Cardiovascular and Cancer.

A report by Grand View Research, for our first offering show’s the global cardiovascular testing market was valued at $32.3 billion in 2019 and is expected to reach $70.2 billion by 2027, at a compound annual growth rate of 10.3%.

The market is driven by factors such as the increasing prevalence of CVD, the growing demand for early diagnosis, and increased spending by National Health Institutions.

Millions of people are unaware they have cardiovascular conditions that may lead to a heart attack. We can provide a test that will inform them in under 10 minutes.

Some of our competitors
Biomerieux | Abbott | Illumina | GenMark | Quidel

Competing: Most of the competing technology is based on PCR invented in the 80’s and antigen testing.
GMD: Technology is new, not an incremental step.

Competing: Technologys are not sensitive enough to detect very early stages of disease.
GMD: Can detect as little as to 1 virion, 1 virus.

Competing: Can take many hours if not days to return results.
GMD: Our technology returns test results in under 10 minutes.

Competing: Many of our competitors tests require extensive sample preparation.
GMD: Zero sample preparation. Just inject and run test.

Competing: Technology is based on PCR/ELISA or Lateral Flow Test.

PCR/ELISA are too slow and expensive but very sensitive.
Lateral Flow Assays are cheap, fast but very insensitive.
GMD:
Is fast less than 10 minutes.
Low-cost.
100x more sensitive than PCR.
10,000 more sensitive that lateral Flow Test.

1. Increase in healthcare spending: Growing healthcare spending is driving increased demand for diagnostic testing services.

2. Increasing demand for cost-effective testing: As healthcare costs rise, there is an increasing demand for cost-effective diagnostic testing.

3. Increased adoption of point-of-care/home diagnostics: Point-of-care/home diagnostics are becoming increasingly popular as they allow patients to receive results quickly and conveniently.

4. The growing prevalence of chronic diseases is driving demand for diagnostic testing services.

The worldwide annual testing market is worth over $200 Billion+.

Demand for early diagnostic devices is in high demand and growing.

Health care costs are spiralling and Health Care institutions are urgently investing in early diagnostics to help reduce costs.

Home testing budget can be auxiliary to NHS thus leading to reduce costs.

The GMD technology has created a new bench mark for speed, accuracy, sensitivity of detection at low-cost.

Increasing demand for point-of-care/home diagnostics.

QbQ – Now offers by far the earliest detection of Viruses, Dementia, Cardiovascular and Cancer

With a working lab device, now ready for commercialisation.

• Experts in DNA sequencing and microfluidics.
• New technology not an incremental step.
• Patented technology.
• Proven technology, backed by science.
• Experienced board and management.
• Ready to commercialise.

The GMD-QbQ is a sealed unit that has a opening to accept samples inserted by a chip.

The chip carries the blood/ saliva sample and has a one time use.

We charge for the sale of the QbQ device plus charge for reagents and each testing chip used.

In high demand environments this could mean (multiple QbQ devices) and hundreds of chips used per day.

Future product is a multiplex-reader (reading multiple chips at a time)

Your money will go towards commercialising the QbQ machine.

Internally assembled benchtop machines with Diagnostic certification.

First sales within 12 months.

We recently secured a grant from INNOVATE UK – Grant amount awarded to GMD £1.6 million. For our world beating technology.

They are other grants we are actively applying for and we will tap in to them as we grow.